Cassava Sciences and two former executives will pay more than $40 million to settle charges related to misleading statements made about a clinical trial for the company's purported therapeutic ...

Flowers decorated with names of loved ones spun in the wind, children ran around filling the sidewalks with affirming messages, smiley faces and games of hopscotch, people pulled their purple shirts ...

Heart disease is the No. 1 killer of Americans. However, having high LDL-C cholesterol levels doesn’t always lead to heart ...

People will join in the fight against Alzheimer’s Disease this Saturday, when the annual Walk to End Alzheimer’s steps off in ...

A woman from Chester Springs, Pennsylvania, is one of the first patients in the country to receive a new FDA-approved ...

Shares of Cassava Sciences Inc. dropped more than 12% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two former ...

In the 1990s, Eli Lilly researched a molecule called xanomeline for Alzheimer’s disease, and found it had potent ...

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.

Barbara Corcoran is one of the most prolific entrepreneurs today. The famous “Shark Tank” host joins New York Living to ...

Federal authorities unsealed a criminal indictment against New York City Mayor Eric Adams on Thursday. Adams vowed to fight ...

The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S. living with schizophrenia.